Celltrion Healthcare Presents Clinical Data Showing That Inflammatory Bowel Disease Patients Should Be Treated With Biosimilar Monoclonal Antibody (mAb) Infliximab

Celltrion Healthcare Presents Clinical Data Showing That Inflammatory Bowel Disease Patients Should Be Treated With Biosimilar Monoclonal Antibody (mAb) Infliximab
Documented clinical experience was recently presented by Celltrion Healthcare’s satellite symposium during the 2014 United European Gastroenterology (UEGW) showing evidence that patients with inflammatory bowel disease (IBD) — Crohn’s disease and ulcerative colitis — should be treated with the biosimilar monoclonal antibody (mAb) infliximab. Infliximab is an anti-TNF therapy suitable for patients with IBD12; it is considered a therapy for controlling disease symptoms over the long term. Biologic therapies for IBD are designed

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *